Roth Capital Comments on Moleculin Biotech, Inc.’s Q1 2024 Earnings (NASDAQ:MBRX)

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Research analysts at Roth Capital decreased their Q1 2024 earnings per share estimates for Moleculin Biotech in a research report issued on Monday, March 25th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of ($3.59) per share for the quarter, down from their previous estimate of ($2.40). The consensus estimate for Moleculin Biotech’s current full-year earnings is ($10.27) per share. Roth Capital also issued estimates for Moleculin Biotech’s Q2 2024 earnings at ($2.82) EPS, Q3 2024 earnings at ($2.41) EPS, Q4 2024 earnings at ($2.53) EPS, FY2024 earnings at ($11.05) EPS, FY2025 earnings at ($8.35) EPS, FY2026 earnings at ($7.35) EPS and FY2027 earnings at $1.83 EPS.

MBRX has been the topic of several other reports. HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of Moleculin Biotech in a research note on Thursday, December 14th. Maxim Group lowered their price target on Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday. Finally, StockNews.com started coverage on Moleculin Biotech in a research report on Thursday. They set a “sell” rating on the stock.

Moleculin Biotech Trading Up 6.7 %

Shares of MBRX stock opened at $5.91 on Thursday. The stock’s 50-day moving average price is $7.83 and its 200-day moving average price is $8.21. Moleculin Biotech has a 12-month low of $4.34 and a 12-month high of $24.75. The stock has a market capitalization of $13.18 million, a price-to-earnings ratio of -0.43 and a beta of 1.98.

Institutional Investors Weigh In On Moleculin Biotech

Several hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. purchased a new position in Moleculin Biotech in the 4th quarter valued at about $39,000. Atticus Wealth Management LLC purchased a new position in Moleculin Biotech in the 4th quarter valued at about $43,000. Citadel Advisors LLC purchased a new position in Moleculin Biotech in the 4th quarter valued at about $55,000. Renaissance Technologies LLC lifted its stake in Moleculin Biotech by 34.7% in the 2nd quarter. Renaissance Technologies LLC now owns 127,400 shares of the company’s stock valued at $74,000 after buying an additional 32,795 shares in the last quarter. Finally, State Street Corp lifted its stake in Moleculin Biotech by 19.2% in the 1st quarter. State Street Corp now owns 71,397 shares of the company’s stock worth $127,000 after purchasing an additional 11,497 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.